

Year-end Report

Fourth quarter and full-year 2025



Saving. Vital. Seconds.

October-December 2025

- Net sales decreased by 12% and amounted to SEK 18.8 (21.3) million.
- The gross margin increased to 41 (21)%.
- EBITDA amounted to SEK -3.9 (-4.4) million.
- Adjusted EBITDA* amounted to SEK -1.6 (2.3) million.*
- Net profit after tax amounted to SEK -7.0 (-9.6) million.
- Earnings per share before and after dilution amounted to SEK -0.10 (-0.22).

January-December 2025

- Net sales decreased by 9% and amounted to SEK 73.4 (80.4) million.
- The gross margin amounted to 40 (35)%.
- EBITDA amounted to SEK -15.9 (-13.8) million.
- Adjusted EBITDA* amounted to SEK -8.6 (-4.9) million.*
- Net profit after tax amounted to SEK -21.9 (-24.9) million.
- Earnings per share before and after dilution amounted to SEK -0.43 (-0.56).

Significant events during and after fourth quarter

- The directed rights issue, which was registered on 3 November and fully subscribed, raised SEK 52 million for the Company after transaction costs.
- Items of a non-recurring nature impacted the quarterly result by SEK 2.2 million. For the full year, non-recurring items amounted to SEK 7.4 million.
- On 13 January, it was announced that Ponderus Invest AB holds 80 per cent of the Company following the mandatory cash offer made in accordance with the Takeover Code.
- In February, Minni Raji joined the Company as Chief Financial Officer.
- The Board of Directors proposes that no dividend be paid for the financial year 2025.

Group's key figures

Amount in tSEK	Q4		Jan-Dec	
	2025	2024	2025	2024
Net sales	18,751	21,262	73,401	80,413
Gross margin	41%	21%	40%	35%
Adjusted gross margin*	53%	47%	43%	42%
EBITDA	-3,855	-4,362	-15,943	-13,846
Adjusted EBITDA*	-1,615	2,273	-8,582	-4,930
Operating results	-6,628	-6,353	-19,805	-19,532
Net profit after tax	-7,027	-9,645	-21,876	-24,903
Equity ratio (%)	32%	-11%	32%	-11%
Earnings per share, before and after dilution, SEK	-0.10	-0.22	-0.43	-0.56
Equity before and after dilution per share, SEK	0.25	-0.16	0.25	-0.16

*See note 6 Alternative performance measures.

CEO's Statement

Innovation and a new generation of MobiMed meet today's growing demand for more efficient digital healthcare solutions.

2025 has been a year marked financially by continued significant non-recurring costs (SEK 7.4 million), but one in which we have not only strengthened our financial foundation and optimised our organisation, but above all have taken decisive steps forward together with our customers. Through strong technological innovation and a consistent focus on close customer partnerships, we have laid a solid foundation for the future and demonstrated the power of our vision: to save lives, improve efficiency, and increase healthcare capacity through the digitalisation of prehospital care.

A strong existing customer base – the foundation of our success

The strongest evidence of the value we create is the continued trust of our customers. During the year, we secured ongoing collaborations with two of England's largest and most important NHS trusts: SWAST (South Western Ambulance Service) and SCAS (South Central Ambulance Service). We also extended contracts with key customers in Singapore and Northern Ireland. These two-year extensions, worth approximately SEK 52 million in total, directly confirm that the MobiMed platform is a critical and valued part of their daily operations and a testament to their confidence in our long-term strategy. To take the UK as an example, we have operated their patient records — currently around 13 million — for over ten years with high operational stability.

Innovation that makes a real difference

2025 will be remembered as the year we launched MobiMed 5, the fifth-generation ambulance patient record and monitoring system, designed to manage clinical data and support healthcare diagnostics. We are pleased that Region Norrbotten became the first customer to deploy this powerful new system. All 17 regions in Sweden that are currently our customers have shown strong interest in the new platform, which is built for modern prehospital care and facilitates increased collaboration with specialist care, primary care, and municipal health services. The MobiMed 5 concept provides comprehensive support from dispatch, navigation, documentation, decision support, communication, handover, to follow-up. The new incident management module enables ambulance teams and management to handle larger-scale events involving multiple casualties, providing critical support for oversight, structured communication, logistics, and coordination. One of the year's most significant innovations is the collaboration agreement with Cambio COSMIC

for the "Read in Cosmic" functionality. For the first time in Sweden, ambulance personnel now have direct access to historical patient data from hospital primary records. This is a revolutionary step for patient safety and a fundamental building block for enabling regions to optimise healthcare resource utilisation. The ability to make informed decisions for mobile care teams, even while in the ambulance, optimises the entire care pathway and increases healthcare capacity.

In Region Jämtland, the implementation of MobiMed enRoute, the next-generation navigation system, has begun, now fully integrated into the MobiMed platform to enable faster and safer responses. To further support our customers' operations, we also launched integration with CGI's Raindance (finance and billing module), helping regions such as Norrbotten reduce administration, save resources in financial processes, and gain improved control over costs and revenue.

Building for the future - with the right platform and team

Technology moves quickly. For example, nearly all UK ambulance services are gradually moving their fleets to the iOS ecosystem. Personnel will receive personal devices (Apple iPads), which will drive license volumes and a new business model for MobiMed. This confirms that we are on the right path with our strategic investment in iOS. Throughout the year, we have continued to develop and invest in our scalable platform and feel well-prepared to lead this transition together with our customers in the UK and globally. To support this growth, we have strengthened our team with key recruitments. Together with our outstanding staff, we have reviewed and improved internal processes and procedures, which has already resulted in an improved gross margin from 35% (2024) to 40% (2025) and an operating result improvement of approximately SEK 3 million.

A solid foundation for growth

We enter 2026 with a strengthened balance sheet, a more efficient organisation, and a portfolio of innovations already making a difference. We continue to see a rise in major tenders in the market and are ready to meet our customers' needs with our digital solutions to improve patient safety and increase healthcare capacity. Challenges will always exist, but the measures we have taken have created a strong foundation for profitable growth. I have great confidence in our team's capabilities and look forward with enthusiasm to what we will achieve in 2026.

GUSTAF NORDENHÖK | Chief Executive Officer

Group development

January – December 2025

Financial performance

Net revenue for the quarter decreased by 12% to SEK 18.8 (21.3) million. For the year, net revenue decreased by 9% to SEK 73.4 (80.4) million. Of the quarter's net revenue, SEK 12.6 million and for the year SEK 41.5 million relate to recurring contracts. For the year SEK 39 (31) million of revenue relates to the UK, and the strengthened SEK resulted in a reduction in net revenue of SEK 2 million compared with the previous year. The gross margin for the quarter was 41% (21%) and 40% (35%) for the year. Research and development costs increased to SEK -3.2 (-1.9) million in the quarter and decreased to SEK -7.7 (-10.8) million for the year. Operating expenses for the quarter amounted to SEK 14.2 (10.8) million and SEK 49.4 (47.5) million for the year. Non-recurring items in the quarter amounted to SEK 2.2 (6.6) million, primarily relating to the mandatory offer, recruitment, and establishment in Australia. The year was also impacted by SEK 5.1 million for a discontinued project in Estonia. Total non-recurring items amounted to SEK 7.4 (8.9) million. Operating profit for the quarter amounted to SEK -6.6 (-6.4) million and SEK -19.8 (-19.5) million for the year. Net financial items, primarily consisting of interest on borrowings and factoring, amounted to SEK -0.2 (-1.6) million for the quarter and SEK -1.9 (-3.6) million for the year, including a positive currency effect of SEK 1.6 million. Profit after tax for the quarter amounted to SEK -7.0 (-9.6) million and SEK -21.9 (-24.9) million for the year, corresponding to earnings per share before and after dilution of -0.10 (-0.22) SEK for the quarter and -0.43 (-0.56) SEK for the year.

Cash flow and liquidity

Cash flow from operating activities for the quarter amounted to SEK -11.9 (11.1) million and for the year SEK -25.2 (-9.7) million. Cash flow from investing activities was SEK -1.1 (-5.6) million for the quarter and SEK -9.6 (-7.6) million for the year. Cash flow from financing activities generated SEK 20.9 (-0.3) million in the quarter and SEK 36.5 (23.3) million for the year. The rights issue contributed a total of SEK 52.1 million, net of transaction of SEK 1.9 million. The Group's total cash flow amounted to SEK 7.9 (5.2) million for the quarter and SEK 1.6 (6.0) million for the year. Cash ad cash equivalents at the end of the year totalled 8.9 (7.3).

Financial position

Assets: Investments in intangible and tangible fixed assets amounted to SEK 38.8 (33.1) million at the end of the year. During the year, investments in intangible and tangible fixed assets amounted to SEK 9.6 (7.6) million, with depreciation of SEK 3.9 (3.8) million. The investments mainly related

to MobiMed Journal for iOS. Financial assets amounted to SEK 2.3 (2.3) million. At the end of the year, inventory totalled SEK 4.7 (7.6) million. Trade receivables amounted to SEK 10.0 (3.4) million. At the end of the year, the Group's equity amounted to SEK 22.4 (-7.2) million, with an equity-to-assets ratio of 32 (-11)%.

The Group

The Group comprises the parent company Ortivus AB (publ), corporate ID 556259-1205, as well as the subsidiaries Ortivus UK Ltd, corporate ID 03558696, Ortivus MobiMed AB, corporate ID 556593-0707, Ortivus MobiMed ApS, CVR 43419110 and Ortivus APAC PTY Ltd, ABN. 89 692 539 290. Ortivus MobiMed ApS is being liquidated and Ortivus APAC PTY Ltd is a newly established standby subsidiary.

Personnel

At the end of the year, the Group employed 38 (48) people, with 2 (2) in the Parent Company. Employees in Sweden numbered 24 (36). The proportion of women was 23% (28%). In addition to employees, seven consultants worked within the organisation on a part-time or project basis.

Annual General Meeting 2026

The Annual General Meeting will be held in Stockholm on 7 May. The Annual Report will be made available on the Company's website, www.ortivus.com, on 31 March. The Board of Directors proposes that no dividend be paid for the financial year 2025.

Related party transactions

The existing credit facility of SEK 20 million from Ponderus Invest AB remains in place until 30 November 2027. Ponderus Invest AB holds 80.3 per cent of the shares and is represented on the Board of Directors.

Shares, share capital and shareholders

Ortivus A and B shares are listed on Nasdaq First North Growth Market. As of December 31, the number of shares was 88.6 million, comprising 1.7 million A shares and 87 million B shares. The number of shareholders was 3,737. The company's market capitalization at the end of the year was SEK 107.8 (64.9) million.

Forward-looking statements

All forward-looking statements in this report are based on the company's best assessment at the time of the report. Such statements involve risks and uncertainties, which may result in actual outcomes differing. Except as required by applicable law, forward-looking statements are valid only as of the date they are made, and Ortivus undertakes no obligation to update any of them in light of new information or future events. Ortivus does not provide forecasts.

Other information

The Parent Company Ortivus AB (publ) conducts group-wide operations. The parent company's net sales during the year amounted to SEK 21.0 (16.2) million. Operating profit amounted to SEK 3.3 (3.0) million. Cash and cash equivalents at the end of the quarter amounted to SEK 1.8 (0.1) million.

Certified Advisor

Certified Adviser on NASDAQ First North Growth Market is FNCA Sweden AB
Box 5807 Nybrogatan 34
102 48 Stockholm
Phone: +46 8 528 00 399

Financial calendar

2025 Annual Report: 31 March 2026
Q1 2026 Report: 7 May 2026
Annual General Meeting: 7 May 2026
Q2 2026 Report: 25 August 2026
Q3 2026 Report: 13 November 2026
Q4 and Full-Year Report: 19 February 2027

Financial information

Ortivus AB (publ) is listed on Nasdaq First North Growth Market. The information in this report is disclosed in accordance with the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication through the agency of the contact persons below on 19 February 2026, at 08:30 a.m. CET. Financial reports and press releases are published in Swedish and English and are available at www.ortivus.com.

This report has not been reviewed by the company's auditor.

For further information:

Gustaf Nordenhök, CEO
Phone: +46(0) 73-2624357
Email: gustaf.nordenhok@ortivus.com

Minni Raji, CFO
Phone: +46(0) 70-6885340
Email: minni.raji@ortivus.com.

Nomination Committee 2026

As a result of the rights issue carried out during the fourth quarter and the subsequent public offer from Ponderus Invest AB, Ponderus Invest now holds approximately 80.3 per cent of the total outstanding shares and approximately 70.1 per cent of the total voting rights in Ortivus. In light of the new ownership structure in Ortivus, the Board of Directors has concluded that, under the current circumstances, it is neither economically nor administratively justified to allocate time and resources to the work of a Nomination Committee. The Company's shareholders will, as always, resolve at the forthcoming Annual General Meeting of Ortivus on all matters that would otherwise fall within the remit of the Nomination Committee.

Assurance

The Board of Directors and the CEO certify that this report provides a fair overview of the Parent Company's and the Group's operations, financial position, and results, and describes the significant risks and uncertainties facing the Parent Company and the companies in the Group.

Danderyd 19-02-2026

Anna-Carin Strandberg

Chairman of the Board

Peter Edwall

Board member

Anna Klevby Dalgaard

Board member

Ulf Järnberg

Board member

Gustaf Nordenhök

Chief Executive Officer

Financial reports

The Group's report on results in summary

Amount in KSEK	Q4		Jan-Dec	
	2025	2024	2025	2024
Net sales	18,751	21,262	73,401	80,413
Cost of sales	-11,142	-16,843	-43,801	-52,478
Gross profit	7,609	4,418	29,600	27,935
Gross margin	41%	21%	40%	35%
Selling expenses	-5,780	-7,058	-20,875	-24,813
Administrative expenses	-5,027	-1,943	-15,466	-11,392
Research and development expenses	-3,173	-1,933	-7,707	-10,805
Other operating income	889	349	1,563	349
Other operating expenses	-1,146	-186	-6,920	-805
Operating profit	-6,628	-6,353	-19,805	-19,532
Operating margin	-35%	-30%	-27%	-24%
Net result from other financial assets	-	-1,690	-	-1,690
Financial net	-186	-1,575	-1,858	-3,596
Profit before tax	-6,814	-9,618	-21,663	-24,817
Tax	-213	-28	-213	-86
Profit for the period	-7,027	-9,645	-21,876	-24,903
Items that may be subsequently reclassified to profit or loss				
Gains/losses arising on translation of the statements of foreign operations	-273	-91	-683	-
Comprehensive income for the period	-7,300	-9,737	-22,559	-24,903
Profit for the period attributable to Owners of the Parent Company	-7,027	-9,645	-21,876	-24,903
Comprehensive income for the period attributable to Owners of the Parent Company	-7,300	-9,737	-22,559	-24,903

The Group's statement of financial position in summary

Amount in KSEK	31/Dec 2025	31/Dec 2024
Fixed assets		
Intangible assets	36,297	28,067
Tangible assets	562	1,192
Right-of-use assets	1,951	3,820
Financial assets	2,347	2,310
Total fixed assets	41,157	35,389
Current assets		
Inventory	4,663	7,610
Accounts receivable	9,965	3,398
Other receivable	906	1,657
Prepaid expenses and accrued income	5,350	8,572
Cash	8,888	7,281
Total current assets	29,772	28,518
TOTAL ASSETS	70,929	63,907
 SHAREHOLDERS' EQUITY	 22,414	 -7,165
PROVISIONS	87	89
Long term liabilities		
Long-term interest-bearing liabilities	-	2,136
Loan	18,000	33,664
Lease liabilities	-	1,981
Total long term liabilities	18,000	37,781
Short term liabilities		
Advance payment from customers	4,459	4,873
Accounts payable	8,165	7,378
Short term liabilities	-	500
Other liabilities	4,256	7,774
Lease liabilities	1,527	1,885
Accrued expenses and prepaid income	12,021	10,792
Total short term liabilities	30,428	33,202
TOTAL LIABILITIES AND EQUITY	70,929	63,907

The Group's statement of changes in equity

Amount in KSEK	31/Dec 2025	31/Dec 2024
Opening balance	-7,165	17,305
Profit for the period	-21,876	-24,903
Rights issue	52,139	-
Currency adjustment	-684	434
Closing balance	22,414	-7,165

The Group's statement of cash flow in summary

Amount in KSEK	Q4		Jan-Dec	
	2025	2024	2025	2024
Profit before tax	-6,812	-9,618	-21,663	-24,817
Adjustments for non-cash items	-5,027	2,991	-1,890	5,141
Cash flow from operating activities before changes in working capital	-11,839	-6,627	-23,553	-19,676
Cash flow from changes in working capital	-18	17,732	-1,684	9,929
Cash flow from operating activities	-11,857	11,105	-25,237	-9,747
Cash flow from investing activities	-1,087	-5,603	-9,630	-7,590
Cash flow from financing activities	20,880	-342	36,475	23,330
Cash flow for the period	7,936	5,160	1,608	5,993
Cash at the beginning of the period	953	2,122	7,281	1,289
Exchange difference in cash	-	-1	-	-
Cash at the end of the period	8,889	7,281	8,889	7,281

The Parent Company's income statement in summary

Amount in KSEK	Q4		Jan-Dec	
	2025	2024	2025	2024
Net sales	6,528	5,445	20,977	16,231
Gross profit	6,528	5,445	20,977	16,231
Gross margin	100%	100%	100%	100%
Administrative expenses	-5,828	-4,564	-17,635	-13,224
Other operating income	-	-	-	13
Other operating expenses	-	-	-	-63
Operating profit	700	880	3,342	2,957
Operating margin	11%	16%	16%	18%
Income from investments in group companies	-	-	-	-50,034
Financial net	-549	-733	-2,876	-2,754
Profit before tax	151	148	466	-49,831
Profit after tax	151	148	466	-49,831

The Parent Company's statement of financial position in summary

Amount in KSEK	31/Dec 2025	31/Dec 2024
Fixed assets		
Intangible assets	1,229	1,230
Participation in group companies	60,009	60,009
Total fixed assets	61,238	61,239
Current assets		
Accounts receivables	-	210
Receivables from group companies	44,162	7,060
Tax receivables	160	146
Other receivables	666	191
Prepaid expenses and accrued income	814	765
Cash	1,831	67
Total current assets	47,633	8,438
TOTAL ASSETS	108,871	69,677
 SHAREHOLDERS' EQUITY	 84,460	 31,855
Long term liabilities		
Long-term loans	18,000	33,664
Total long term liabilities	18,000	33,664
Short term liabilities		
Advance payments from customers	350	375
Accounts payable	3,946	1,183
Liabilities to group company	-	278
Other liabilities	219	78
Accrued expenses and prepaid income	1,896	2,244
Total short term liabilities	6,411	4,158
TOTAL LIABILITIES AND EQUITY	108,871	69,677

The Parent Company's statement of changes in equity

Amount in KSEK	31/Dec 2025	31/Dec 2024
Opening balance	31,855	81,686
Rights issue	52,139	-
Profit of the year	466	-49,831
Closing balance	84,460	31,855

Note 1 General information

Ortivus AB (publ), corporate identity number 556259-1205, is a Swedish public limited company with its registered office in Danderyd. The head office is located at Svärdevägen 19, SE-182 33 Danderyd, Sweden. The Group provides digital medical technology and eHealth solutions, specifically developed for out-of-hospital care. Unless otherwise stated, all amounts are reported in thousands of SEK (KSEK). Figures in parentheses refer to the comparative year. This report was approved for publication by the Board of Directors on 19 February 2026.

Note 2 Accounting principles

This report for the Group has been prepared in accordance with IAS 34 Interim Financial Reporting and the Swedish Annual Accounts Act. The report for the Parent Company has been prepared in accordance with the Swedish Annual Accounts Act. The same accounting and valuation principles have been applied for the Group and the Parent Company as in the most recently published annual report. Significant estimates and judgements are described in Note 29 of the 2024 Annual Report. No changes have been made to these that could have a material impact on the current report. New standards, amendments, and interpretations effective from 1 January 2025 or later have had no impact on this report.

Note 3 Significant risks and uncertainties

Due to the nature of its operations, Ortivus is exposed to various types of risks. The Board's work on risk management is outlined in Note 26 of the 2024 annual report.

Note 4 Revenue distribution

The Group has only one operating segment, which is fully reflected in the Group's financial reports. Revenue is distributed geographically as shown in the table below.

	Q4		Jan-Dec	
	2025	2024	2025	2024
Nordics	9,296	10,969	31,787	43,450
Rest of Europe	9,106	9,918	40,071	35,419
Rest of the World	349	375	1,543	1,544
Total	18,751	21,262	73,401	80,413

Note 5 Significant exchange rates

31 December 2025	EUR	GBP	SGD	USD	AUD
Closing rate	10.82	12.42	7.17	9.20	6.17
Annual average exchange rate	11.07	12.92	7.51	9.82	6.32
31 December 2024	EUR	GBP	SGD	USD	AUD
Closing rate	11.49	13.85	8.11	11.00	6.86
Annual average exchange rate	11.43	13.50	7.91	10.56	6.97

Note 6 Alternative performance measures

Ortivus applies the European Securities and Markets Authority's (ESMA) guidelines for so-called Alternative Performance Measures (APMs). The company's management considers these alternative performance measures to be relevant for users of the financial report as a complement to the metrics that reflect the company's operational development. These financial measures are not always comparable with those used by other companies, as not all companies calculate such measures in the same way. Therefore, these financial measures should not be regarded as substitutes for measures defined in accordance with IFRS.

Definitions of key performance indicators

The Group

Gross margin - Gross profit as a percentage of net sales. The company believes that key figures provide a deeper understanding of the company's profitability.

Amount in KSEK	Q4		Jan-Dec	
	2025	2024	2025	2024
Gross profit/	7,609	4,418	29,600	27,935
Net sales	18,751	21,262	73,401	80,413
Gross margin	41%	21%	40%	35%

Adjusted gross margin - Adjusted gross margin for non-recurring items. Significant events and transactions that are relevant when comparing results between periods are highlighted. Non-recurring items comprise restructuring costs, consultancy fees, costs related to staff reductions, contract losses, impairments, significant customer losses, as well as legal disputes and insurance claims. Non-recurring items are excluded to facilitate comparison of results across periods.

Amount in KSEK	Q4		Jan-Dec	
	2025	2024	2025	2024
Gross profit	7,609	4,418	29,600	27,935
Non-recurring items	2,240	5,500	2,240	5,500
Adjusted gross profit/	9,849	9,918	31,840	33,435
Net sales	18,751	21,262	73,401	80,413
Adjusted gross margin	53%	47%	43%	42%

Operating margin - Operating margin as a percentage of net sales. The Company believes that key figures provide a deeper understanding of the company's profitability.

Amount in KSEK	Q4		Jan-Dec	
	2025	2024	2025	2024
Operating results/	-6,628	-6,353	-19,805	-19,532
Net sales	18,751	21,262	73,401	80,413
Operating margin	-35%	-30%	-27%	-24%

EBITDA - Operating profit before net interest, tax, depreciation of tangible and intangible fixed assets. The Company believes that the key figure provides a deeper understanding of the company's profitability.

Amount in KSEK	Q4		Jan-Dec	
	2025	2024	2025	2024
Profit before tax	-6,814	-9,618	-21,663	-24,817
Financial net	186	3,265	1,858	5,286
Depreciation	2,773	1,991	3,862	5,686
EBITDA	-3,855	-4,362	-15,943	-13,845

Adjusted EBITDA - Adjusted EBITDA for non-recurring items. Significant events and transactions that are relevant when comparing results between periods are highlighted. Non-recurring items comprise restructuring costs, such as consultancy fees, staff reductions, contract losses, and impairments. Non-recurring items are excluded to facilitate comparability of results across periods.

Amount in KSEK	Q4		Jan-Dec	
	2025	2024	2025	2024
EBITDA	-3,855	-4,362	-15,943	-13,846
Non-recurring items	2,240	6,635	7,361	8,915
Adjusted EBITDA	-1,615	2,273	-8,582	-4,930

Equity ratio - Equity as a percentage of total assets. Equity ratio shows what proportion of the balance sheet total is made up of equity and has been included so that investors can form a picture of the company's capital structure.


Amount in KSEK	Q4		Jan-Dec	
	2025	2024	2025	2024
Equity	22,414	-7,165	22,414	-7,165
The balance sheet	70,929	63,907	70,929	63,907
Equity ratio	32%	-11%	32%	-11%

Earnings per share - Profit after tax divided by the average number of shares for the period.

Amount in KSEK	Q4		Jan-Dec	
	2025	2024	2025	2024
Profit after tax	-7,027	-9,618	-21,876	-24,903
Average number of shares for the period (a thousand pcs)	72,722	44,307	51,469	44,307
Earnings per share	-0.10	-0.22	-0.43	-0.56

Equity per share - Equity at the end of the period divided by the number of shares at the end of the period. The Company considers this key figure to provide a deeper understanding of the company's profitability.

Amount in KSEK	31 Dec		31 Dec	
	2025	2024	2025	2024
Equity at the end of the period/	22,414			-7,165
Number of shares at the end of the period	88,615			44,307
Equity per share	0.25			-0.16



Ortivus platform

MobiMed

MobiMed ePR

MobiMed ePR gathers all essential patient information in an intuitive interface, making it easier to make informed decisions in real time and ensuring high-quality care documentation.

MobiMed Monitor

MobiMed Monitor enables real-time monitoring of vital signs directly in the ambulance, providing a stronger basis for decision-making during emergency interventions.

MobiMed FleetCtrl

MobiMed FleetCtrl offers automated checks, status monitoring, and seamless communication between vehicles and personnel, reducing operational disruptions and improving availability.

MobiMed enRoute

MobiMed enRoute combines advanced navigation with case management, facilitating planning, communication, and follow-up during every mission.

MobiMed Life

MobiMed Life is a portable, standalone defibrillator solution that provides immediate access to life-saving treatment and complements the ambulance's existing equipment.

Ortivus

To ensure a smooth and efficient healthcare chain

Our vision

To support healthcare organisations in providing the best care to their patients.

Our mission

To develop and implement innovative software solutions that improve diagnostics, documentation and patient outcomes in the delivery of care.

Our business idea

To provide a digital platform for ambulance and prehospital care that optimises patient flows in real time.



Ortivus AB

Address

Box 713
Svärdvägen 19
182 33 Danderyd
Sweden

Email

info@ortivus.com

www.ortivus.com

Phone

+ 46 8 446 45 00



Saving. Vital. Seconds.